Streetbeat News

ARDS

Aridis Pharmaceuticals Inc

Employees

Industry

Research and Development in Biotechnology

aridis is a privately held infectious diseases focused company in san jose, ca, usa. aridis’ advanced formulation and delivery technologies are combined with proprietary products portfolio to create potent drug candidates that are packaged into convenient to administer, "ready-to-use" formats.

Open

0.00

Mkt cap

4.5K

Volume

10K

High

0.00

P/E Ratio

N/A

52-wk high

0.10

Low

0.00

Div yield

N/A

52-wk low

0.00

Aridis Pharmaceuticals has received approval from the European Medicines Agency (EMA) for the clinical study design and a single confirmatory Phase 3 study of AR-301. This is a significant step forward for the company's drug development program.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 8:09 pm

Several stocks experienced significant movement in Monday's mid-day session. ProMIS Neurosciences, Acumen Pharmaceuticals, BridgeBio Pharma, Lixte Biotechnology Holdings, and Healthcare Triangle were among the top gainers, with shares jumping due to various reasons such as positive preclinical data, successful Phase 1 studies, and strong financial results. On the other hand, Novan, ViewRay, UTime Limited, Jiuzi Holdings, and BYND Cannasoft Enterprises were among the biggest losers, with shares falling due to factors such as asset sales, Chapter 11 filings, and direct offerings.

Portfolio Pulse from Lisa Levin

July 17, 2023 | 5:14 pm

The article lists the stocks that gained and lost the most in Friday's mid-day session. Among the gainers, PainReform Ltd. (PRFX) shares climbed 103% after announcing pricing of a $2.7 million concurrent registered direct offering and private placement. Frequency Therapeutics, Inc. (FREQ) gained 41.7% after agreeing to merge with Korro Bio. Among the losers, Theseus Pharmaceuticals, Inc. (THRX) shares dipped 69.9% after discontinuing enrollment in Phase 1/2 study and terminating development of THE-630 for gastrointestinal stromal tumors. State Street Corporation (STT) fell 10.5% after reporting slightly worse-than-expected second-quarter revenues and an increase in total expenses.

Portfolio Pulse from Lisa Levin

July 14, 2023 | 4:54 pm

Aehr Test Systems (NASDAQ:AEHR) shares rose 4.4% in pre-market trading after reporting better-than-expected results for its fourth quarter. The company expects FY24 revenue to be at least $100 million and GAAP net income of at least $28 million. Other notable pre-market movers include Ainos, Inc. (NASDAQ:AIMD), Intuitive Machines, Inc. (NASDAQ:LUNR), Nikola Corporation (NASDAQ:NKLA), and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

Portfolio Pulse from Lisa Levin

July 14, 2023 | 12:16 pm

During Thursday's after-market session, several health care stocks experienced significant movements. Ainos (AIMD), ACADIA Pharmaceuticals (ACAD), GT Biopharma (GTBP), Centessa Pharmaceuticals (CNTA), Zynerba Pharmaceuticals (ZYNE), and Eterna Therapeutics (ERNA) saw their shares increase, with Ainos leading the gainers with an 84.9% increase. On the other hand, Theseus Pharmaceuticals (THRX), Petros Pharma (PTPI), Molecular Templates (MTEM), Bluejay Diagnostics (BJDX), Adamis Pharmaceuticals (ADMP), and Aridis Pharmaceuticals (ARDS) saw their shares fall, with Theseus Pharmaceuticals leading the losers with a 71.4% decrease.

Portfolio Pulse from Benzinga Insights

July 13, 2023 | 9:38 pm

The article lists the stocks that gained and lost the most during Wednesday's mid-day trading session. Among the gainers were Healthcare Triangle, Ault Alliance, and Recursion Pharmaceuticals, which saw significant increases due to various positive developments. On the other hand, PainReform, CBL International, and Katapult Holdings were among the biggest losers, with their stocks declining due to various negative developments.

Portfolio Pulse from Lisa Levin

July 12, 2023 | 4:53 pm

In Wednesday's pre-market session, several healthcare stocks saw significant movement. Gainers included Recursion Pharmaceuticals (RXRX), Healthcare Triangle (HCTI), Cadrenal Therapeutics (CVKD), Aridis Pharmaceuticals (ARDS), Avrobio (AVRO), and Eloxx Pharmaceuticals (ELOX). Losers included Silk Road Medical (SILK), Biodexa Pharmaceuticals (BDRX), BiomX (PHGE), Cingulate (CING), CytoMed Therapeutics (GDTC), and Vincerx Pharma (VINC).

Portfolio Pulse from Benzinga Insights

July 12, 2023 | 1:12 pm

Aridis Pharmaceuticals has received FDA Qualified Infectious Disease Product Designation for its product AR-301, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

July 12, 2023 | 12:17 pm

Aridis Pharmaceuticals has announced that its product AR-301 has received the FDA's Qualified Infectious Disease Product designation. This designation will expedite the development and review process of the drug.

Portfolio Pulse from Benzinga Newsdesk

July 12, 2023 | 12:02 pm

Aridis Pharmaceuticals announced that its AR-301 program has been deemed eligible for consideration under the FDA Limited Population Pathway for Antibacterial and Antifungal Drugs.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2023 | 12:04 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.